STAT

Introducing the nominees for best biopharma CEO of 2018. Vote for your favorite!

Time for an annual tradition: the best biopharma CEOs of 2018. Vote for your favorite!

It’s been a roller-coaster year in biopharma. The Food and Drug Administration set a new record for drug approvals, and investors bought a record number of biotech initial public offerings. But the performance of those IPOs has been mixed and the most closely followed biotech stock index is negative for the year. For all the volatility on the business side of biotech, the industry’s ability to translate science into new medicines marches on — for now.

The end of the year also offers an opportunity: To determine the best biopharma CEO of, this process is about more than just whimsy. I pored over spreadsheets, dug deep into medical journals, stared at stock charts, and consulted others while coming up with a list of finalists. A few worthy candidates didn’t make the cut.

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About A GLP-1 Side Effect, U.K. Clinical Trial Transparency, And More
A new study links GLP-1 drugs like Ozempic to a higher risk of aspiration pneumonia — a lung infection caused by food breathed into the lungs — after endoscopies.
STAT1 min read
STAT+: Medicare Expected To Negotiate Obesity Drug Prices Soon, New Analysis Predicts
Medicare will likely choose the obesity drug semaglutide for price negotiation “within the next few years,” according to a new analysis.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About An AstraZeneca Deal, A WHO Pandemic Pact, And More
AstraZeneca agreed to acquire Fusion Pharmaceuticals in a deal worth more than $2 billion, picking up a company focused on targeted radiation therapies for cancer.

Related Books & Audiobooks